Sigma Planning Corp Acquires 766 Shares of Medtronic PLC $MDT

Sigma Planning Corp grew its holdings in Medtronic PLC (NYSE:MDT) by 1.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 44,062 shares of the medical technology company’s stock after purchasing an additional 766 shares during the period. Sigma Planning Corp’s holdings in Medtronic were worth $3,841,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. 1248 Management LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at $26,000. Twin Tree Management LP acquired a new stake in shares of Medtronic during the 1st quarter valued at $29,000. Activest Wealth Management boosted its holdings in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares in the last quarter. Hughes Financial Services LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at $32,000. Finally, Investment Management Corp VA ADV boosted its holdings in shares of Medtronic by 144.2% during the 1st quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 238 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William R. Jellison purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director owned 5,000 shares in the company, valued at $461,850. This trade represents a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.26% of the stock is owned by insiders.

Medtronic Stock Down 0.6%

Shares of NYSE:MDT opened at $90.19 on Tuesday. The company has a market capitalization of $115.68 billion, a price-to-earnings ratio of 24.84, a P/E/G ratio of 2.42 and a beta of 0.78. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The business’s 50-day moving average is $94.31 and its 200-day moving average is $89.82. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. The company had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm’s revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic’s payout ratio is currently 78.24%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. Citigroup raised their price objective on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $98.00 target price on shares of Medtronic in a report on Friday. Finally, The Goldman Sachs Group cut their target price on Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.